Douglas Monieson - CME Independent Director
| CME Stock | USD 209.65 1.23 0.59% |
Director
Mr. Douglas M. Monieson is an Independent Director of the Company. Mr. Monieson was a member and active futures trader on CME for 25 years. He is a member of CME, CBOT, NYMEX and COMEX. He serves on our political action and pit supervision committees. Mr. Monieson is a founding member of the NASDAQ 100 pit and served as the pit vicechairman from 19972001. Mr. Monieson is an active fintech angel investor and Chairman Emeritus and board member of Hyde Park Angels, a leading Chicagobased angel investment group. Mr. Monieson has extensive board experience in nominating, compensation and audit and serves on the board of several venture backed companies. Through Hyde Park Angels, he has worked with CME Ventures, the CME Group Foundation and the Futures Industry Association to identify and showcase new and disruptive technology affecting our industry since 2016.
| Age | 50 |
| Tenure | 8 years |
| Address | 20 South Wacker Drive, Chicago, IL, United States, 60606 |
| Phone | 312 930 1000 |
| Web | https://www.cmegroup.com |
CME Management Efficiency
The company has Return on Asset of 0.0142 % which means that on every $100 spent on assets, it made $0.0142 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1203 %, implying that it generated $0.1203 on every 100 dollars invested. CME's management efficiency ratios could be used to measure how well CME manages its routine affairs as well as how well it operates its assets and liabilities. At present, CME's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.03, whereas Return On Equity is forecasted to decline to 0.12. At present, CME's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 99.6 B, whereas Other Assets are forecasted to decline to about 127.7 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Melissa Arnoldi | Nasdaq Inc | 45 | |
| Zig Serafin | Moodys | 47 | |
| Robert Reid | Intercontinental Exchange | 80 | |
| Jorge Bermudez | Moodys | 69 | |
| Michael Rake | SP Global | 69 | |
| John Markese | Nasdaq Inc | 68 | |
| Rebecca Jacoby | SP Global | 59 | |
| Ewald Kist | Moodys | 73 | |
| Marco Alvera | SP Global | 46 | |
| Charles Crisp | Intercontinental Exchange | 73 | |
| Hugh Zentmyer | Morningstar | 70 | |
| Charlene Begley | Nasdaq Inc | 51 | |
| Paul Sturm | Morningstar | 68 | |
| Winfried Bischoff | SP Global | 73 | |
| Gregory Washington | SP Global | 55 | |
| Therese Esperdy | Moodys | 60 | |
| Sharon Bowen | Intercontinental Exchange | 64 | |
| Jacques Perold | MSCI Inc | 62 | |
| Kathryn Hill | Moodys | 64 | |
| Marcus Smith | MSCI Inc | 54 | |
| Benjamin DuPont | MSCI Inc | 56 | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0142 |
CME Group Leadership Team
Elected by the shareholders, the CME's board of directors comprises two types of representatives: CME inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CME. The board's role is to monitor CME's management team and ensure that shareholders' interests are well served. CME's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CME's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ana Dutra, Independent Director | ||
| Daniel Glickman, Independent Director | ||
| Howard Siegel, Independent Director | ||
| Kathleen Cronin, Senior Managing Director, General Counsel, Corporate Secretary | ||
| Dennis Chookaszian, Independent Director | ||
| Kendal Vroman, Chief Officer | ||
| Michel Everaert, MD EMEA | ||
| Steven Wollack, Independent Director | ||
| William Miller, Independent Director | ||
| Derek Sammann, Senior Managing Director - Financial Products and Services | ||
| Cees Vermaas, Managing Director & CEO of CME Europe Limited | ||
| Gedon Hertshten, Independent Director | ||
| Sean Keating, MD Office | ||
| Elizabeth Cook, Independent Trustee | ||
| Daniel Kaye, Director | ||
| Douglas Monieson, Independent Director | ||
| William Knottenbelt, Senior Managing Director, Europe, Middle East, Africa (EMEA) | ||
| John Pietrowhicz, Senior Managing Director - Business Development and Corporate Finance | ||
| Jeffrey Bernacchi, Independent Director | ||
| James Oliff, Independent Director | ||
| Sunil Cutinho, President - CME Clearing | ||
| Julie Holzrichter, COO and Sr. Managing Director | ||
| Timothy Bitsberger, Independent Director | ||
| Bryan Durkin, Chief Commercial Officer and Sr. Managing Director | ||
| Patrick Maloney, Independent Director | ||
| Dennis Suskind, Independent Director | ||
| Alex Pollock, Lead Independent Director | ||
| Leo Melamed, Chairman Emeritus | ||
| Charles Carey, Vice Chairman of the Board | ||
| Hilda Piell, Chief Human Resource Officer, Senior Managing Director | ||
| Kimberly Taylor, President of Global Operations, Technology and Risk | ||
| David Wescott, Independent Director | ||
| Anita Liskey, Senior Communications | ||
| Edemir Pinto, Independent Director | ||
| Deborah Lucas, Independent Director | ||
| John Sandner, Director | ||
| Jack Tobin, Chief Accounting Officer, Managing Director | ||
| Larry Gerdes, Independent Director | ||
| Phupinder Gill, CEO, Director, Member of Competitive Markets Advisory Council, Member of Executive Committee and Member of Strategic Steering Committee | ||
| Linda Rich, Senior Managing Director - Government Relations and Legislative Affairs | ||
| Terry Savage, Independent Director | ||
| Bruce Johnson, Independent Director | ||
| Jonathan Marcus, Senior Counsel | ||
| Julie Winkler, Senior Managing Director - Research and Product Development | ||
| Ronald Pankau, Independent Director | ||
| Kevin Kometer, CIO, Senior Managing Director | ||
| Robert Zagotta, Senior Managing Director - Products and Services | ||
| Lynne Fitzpatrick, Chief Officer | ||
| Yra Harris, Director | ||
| Jill Harley, Managing Director | ||
| Terrence Duffy, Executive Chairman and President Member of Competitive Markets Advisory Council, Chairman of Executive Committee and Member of Strategic Steering Committee | ||
| Edward Gogol, Managing Solutions | ||
| Michael Spencer, Director | ||
| John Peschier, Managing Relations | ||
| Jason Weller, Managing Strategy | ||
| Martin Gepsman, Independent Director | ||
| William Hobert, Independent Trustee | ||
| Christopher Bowen, Chief MD | ||
| Elizabeth Gisch, Managing Management | ||
| Sean Tully, Senior Managing Director - Interest Rates, OTC Products | ||
| Eileen Keeve, Managing Devel | ||
| William Shepard, Independent Director | ||
| Kevin Lennon, Managing Estate |
CME Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CME a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0142 | ||||
| Profit Margin | 0.58 % | ||||
| Operating Margin | 0.62 % | ||||
| Current Valuation | 76.33 B | ||||
| Shares Outstanding | 360.02 M | ||||
| Shares Owned By Insiders | 0.45 % | ||||
| Shares Owned By Institutions | 89.60 % | ||||
| Number Of Shares Shorted | 4.42 M | ||||
| Price To Earning | 32.83 X |
Pair Trading with CME
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CME position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CME will appreciate offsetting losses from the drop in the long position's value.Moving together with CME Stock
| 0.86 | ICE | Intercontinental Exchange Financial Report 2nd of May 2024 | PairCorr |
Moving against CME Stock
| 0.69 | DHIL | Diamond Hill Investment | PairCorr |
| 0.68 | FG | FG Annuities Life Financial Report 1st of May 2024 | PairCorr |
| 0.54 | SPGI | SP Global Earnings Call This Week | PairCorr |
| 0.48 | BY | Byline Bancorp Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to CME could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CME when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CME - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CME Group to buy it.
The correlation of CME is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CME moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CME Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CME can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for CME Stock analysis
When running CME's price analysis, check to measure CME's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CME is operating at the current time. Most of CME's value examination focuses on studying past and present price action to predict the probability of CME's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CME's price. Additionally, you may evaluate how the addition of CME to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is CME's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CME. If investors know CME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CME listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.276 | Dividend Share 4.4 | Earnings Share 8.85 | Revenue Per Share 15.512 | Quarterly Revenue Growth 0.192 |
The market value of CME Group is measured differently than its book value, which is the value of CME that is recorded on the company's balance sheet. Investors also form their own opinion of CME's value that differs from its market value or its book value, called intrinsic value, which is CME's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CME's market value can be influenced by many factors that don't directly affect CME's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CME's value and its price as these two are different measures arrived at by different means. Investors typically determine if CME is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CME's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.